Pfizer profit misses as breast cancer drug sales fall short of estimates
Reuters
Published Jan 28, 2020 12:47PM ET
Pfizer profit misses as breast cancer drug sales fall short of estimates
(Reuters) - Pfizer Inc (N:PFE) posted a quarterly profit on Tuesday that came in below Wall Street estimates, as sales of breast cancer drug Ibrance fell short of expectations.
Under Albert Bourla, who took the helm at the start of last year, Pfizer has streamlined operations and announced plans to separate its off-patent branded drugs business, Upjohn, and combine it with generic drugmaker Mylan NV (O:MYL).
The company said it expects 2020 adjusted earnings per share to be in the range $2.82 to $2.92. Excluding Upjohn unit, it expects full-year adjusted earnings in the range $2.25 to $2.35 per share.
Sales of breast cancer drug Ibrance rose 13.2% to $1.28 billion in the fourth quarter, but missed the consensus estimate of $1.35 billion, according to IBES data from Refinitiv.
Revenue fell 9% to $12.69 billion, partly hurt by intense competition for its pain treatment Lyrica that lost patent protection last year.
Excluding items, it earned 55 cents per share, missing the average analyst estimate of 58 cents per share.
Net loss attributable to Pfizer narrowed to $337 million, or 6 cents per share, in the quarter, from $394 million, or 7 cents per share, a year earlier.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.